Citigroup’s Oramed Pharmaceuticals ORMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $76K | Buy |
15,808
+6,819
| +76% | +$27.1K | ﹤0.01% | 4829 |
|
|
2026
Q1 | $30.6K | Buy |
+8,989
| New | +$30.5K | ﹤0.01% | 4695 |
|
|
2025
Q4 | – | Sell |
-4
| Closed | -$11 | – | 6346 |
|
|
2025
Q3 | $11 | Buy |
+4
| New | +$9 | ﹤0.01% | 5939 |
|
|
2023
Q4 | – | Sell |
-41,471
| Closed | -$108K | – | 5816 |
|
|
2023
Q3 | $108K | Buy |
41,471
+4,027
| +11% | +$12.7K | ﹤0.01% | 3902 |
|
|
2023
Q2 | $134K | Buy |
37,444
+12,388
| +49% | +$39.7K | ﹤0.01% | 4096 |
|
|
2023
Q1 | $54.6K | Sell |
25,056
-40,834
| -62% | -$130K | ﹤0.01% | 4229 |
|
|
2022
Q4 | $793K | Buy |
65,890
+35,246
| +115% | +$274K | ﹤0.01% | 2834 |
|
|
2022
Q3 | $199K | Buy |
30,644
+27,061
| +755% | +$219K | ﹤0.01% | 3784 |
|
|
2022
Q2 | $16K | Buy |
3,583
+1,138
| +47% | +$6.08K | ﹤0.01% | 5129 |
|
|
2022
Q1 | $21K | Sell |
2,445
-5,839
| -70% | -$59.8K | ﹤0.01% | 5119 |
|
|
2021
Q4 | $118K | Buy |
8,284
+4,839
| +140% | +$101K | ﹤0.01% | 4645 |
|
|
2021
Q3 | $76K | Buy |
3,445
+74
| +2% | +$1.26K | ﹤0.01% | 4526 |
|
|
2021
Q2 | $45K | Sell |
3,371
-621
| -16% | -$7.1K | ﹤0.01% | 4878 |
|
|
2021
Q1 | $41K | Sell |
3,992
-4,708
| -54% | -$38.6K | ﹤0.01% | 4815 |
|
|
2020
Q4 | $37K | Hold |
8,700
| – | – | ﹤0.01% | 6246 |
|
|
2020
Q3 | $23K | Hold |
8,700
| – | – | ﹤0.01% | 6096 |
|
|
2020
Q2 | $31K | Hold |
8,700
| – | – | ﹤0.01% | 6294 |
|
|
2020
Q1 | $26K | Sell |
8,700
-800
| -8% | -$3.5K | ﹤0.01% | 6509 |
|
|
2019
Q4 | $49K | Hold |
9,500
| – | – | ﹤0.01% | 6326 |
|
|
2019
Q3 | $30K | Hold |
9,500
| – | – | ﹤0.01% | 6470 |
|
|
2019
Q2 | $34K | Hold |
9,500
| – | – | ﹤0.01% | 6778 |
|
|
2019
Q1 | $35K | Hold |
9,500
| – | – | ﹤0.01% | 6623 |
|
|
2018
Q4 | $29K | Hold |
9,500
| – | – | ﹤0.01% | 6668 |
|
|
2018
Q3 | $46K | Buy |
9,500
+2,100
| +28% | +$10.9K | ﹤0.01% | 6589 |
|
|
2018
Q2 | $55K | Buy |
7,400
+855
| +13% | +$6.2K | ﹤0.01% | 6218 |
|
|
2018
Q1 | $43K | Buy |
+6,545
| New | +$50.5K | ﹤0.01% | 6275 |
|
|
2016
Q1 | – | Sell |
-73
| Closed | -$1K | – | 7674 |
|
|
2015
Q4 | $1K | Buy |
+73
| New | +$553 | ﹤0.01% | 7401 |
|
|
2015
Q2 | – | Sell |
-115
| Closed | – | – | 7681 |
|
|
2015
Q1 | $0 | Buy |
+115
| New | +$555 | ﹤0.01% | 7360 |
|
|
2014
Q4 | – | Sell |
-3,000
| Closed | -$24K | – | 7250 |
|
|
2014
Q3 | $24K | Buy |
3,000
+1,000
| +50% | +$8.89K | ﹤0.01% | 5796 |
|
|
2014
Q2 | $19K | Buy |
2,000
+1,000
| +100% | +$10.2K | ﹤0.01% | 5834 |
|
|
2014
Q1 | $12K | Buy |
1,000
+700
| +233% | +$11.8K | ﹤0.01% | 6265 |
|
|
2013
Q4 | $5K | Buy |
+300
| New | +$2.31K | ﹤0.01% | 6609 |
|
Other funds holding ORMP
AF
GIA
M
BCM
BFM
Citigroup's ORMP Position: Q2 2026 in Review
Citigroup increased its Oramed Pharmaceuticals (ORMP) stake by 76% in Q2 2026, buying an estimated $27.1K and bringing the position to 15,808 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #4829.
Citigroup first reported a position in ORMP in Q4 2013 and has held it in 32 quarters since. The position peaked at $793K in Q4 2022. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.
- Citigroup held 15,808 shares of Oramed Pharmaceuticals worth $76K as of Q2 2026.
- Citigroup bought 6,819 Oramed Pharmaceuticals shares in Q2 2026, an estimated $27.1K.
- Oramed Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4829 holding.
- Citigroup first reported a position in Oramed Pharmaceuticals in Q4 2013 and has held it in 32 quarters since.
- Citigroup's Oramed Pharmaceuticals position peaked at $793K in Q4 2022.
- 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.